Filaria: river blindness
Developing a rapid cure for millions at risk of blindness
Filaria: river blindness
Developing a rapid cure for millions at risk of blindness
With a portfolio of four R&D projects, we are advancing the pre-clinical development of new drug candidates to develop a safe, effective, field-adapted treatment.
Filarial diseases are a debilitating group of diseases caused by parasitic worms transmitted by the bite of blood-feeding insects. People are infected with river blindness (also known as onchocerciasis) by repeated exposure to blackflies that breed in fast-flowing rivers. The flies transmit worms that can cause severe itching and disfiguring skin lesions, and repeated infection can lead to blindness. Millions of people in sub-Saharan Africa are at risk.
Treatments that can kill adult filarial worms and be used for individual patient treatment are urgently needed. The current approach to eliminating river blindness is based on the mass distribution of ivermectin. While successful in reducing the prevalence of the disease, these programmes need to be repeated for 10-12 years because the drug only kills juvenile worms – not the adult worms, which can live for more than ten years in the human body.
‘Sometimes I cry all night, sometimes from suffering, sometimes from misery, and sometimes from poverty… My heart hurts from my lack of hope. I live a life of suffering.’
What we have achieved
We have built a portfolio of four R&D projects for river blindness and are pursuing the pre-clinical development of drug candidates.
What we are doing for people with river blindness
We aim to complete development and register at least one new drug for river blindness. We are also seeking to identify potential new drug candidates by evaluating registered drugs, as well as pre-clinical and clinical drug candidates to populate the empty drug pipeline.
Making medical history for neglected patients
We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.
